Department of Biochemistry, Molecular and Structural Biology, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia.
Biochimie. 2010 Nov;92(11):1597-607. doi: 10.1016/j.biochi.2010.05.012. Epub 2010 May 26.
Many questions in the field of protein aggregation to amyloid fibrils remain open. In this review we describe predominantly in vitro studies of oligomerization and amyloid fibril formation by human stefins A and B. In human stefin B amyloidogenesis in vitro we have observed some general and many specific properties of its prefibrillar oligomers and amyloid fibrils. One characteristic feature in common to stefins and cystatins (and possibly some other amyloid proteins) is domain-swapping. In addition to solution structure of the domain-swapped dimer of stefin A, we recently have determined 3D structure of stefin B tetramer, which proved to be composed from two domain-swapped dimers, whose interaction occurs by a proline switch in the loop surrounding the conserved Pro 74. Studying the mechanism of fibril formation by stefin B, we found that the nucleation and fibril elongation reactions have energies of activation (E(a)'s) in the range of proline isomerisation, strongly indicating importance of the Pro at site 74 and/or other prolines in the sequence. Correlation between toxicity of the prefibrillar oligomers and their interaction with acidic phospholipids was demonstrated. Stefin B was shown to interact with amyloid-beta peptide of Alzheimer's disease in an oligomer specific manner, both in vitro and in the cells. It also has been shown that endogenous stefin B (with E at site 31) but especially the EPM1 mutant R68X and Y31-stefin B variant, and to a lesser extent EPM1 mutant G4R, are prone to form aggregates in cells.
许多关于蛋白质聚集到淀粉样纤维的问题仍然没有答案。在这篇综述中,我们主要描述了人源组织蛋白酶抑制剂 A 和 B 的寡聚化和淀粉样纤维形成的体外研究。在人源组织蛋白酶抑制剂 B 的淀粉样纤维生成的体外研究中,我们观察到了其前纤维寡聚体和淀粉样纤维的一些普遍特征和许多特殊特征。组织蛋白酶抑制剂和胱抑素(可能还有一些其他淀粉样蛋白)共有的一个特征是结构域交换。除了组织蛋白酶抑制剂 A 的结构域交换二聚体的溶液结构外,我们最近还确定了组织蛋白酶抑制剂 B 的四聚体的 3D 结构,证明其由两个结构域交换二聚体组成,其相互作用通过保守的 Pro74 周围环上的脯氨酸开关发生。在研究组织蛋白酶抑制剂 B 的纤维形成机制时,我们发现成核和纤维延伸反应的活化能(E(a))在脯氨酸异构化范围内,这强烈表明 74 位 Pro 以及/或者序列中的其他脯氨酸的重要性。还证明了前纤维寡聚体的毒性与其与酸性磷脂的相互作用之间存在相关性。组织蛋白酶抑制剂 B 被证明以寡聚体特异性的方式与阿尔茨海默病的淀粉样β肽相互作用,无论是在体外还是在细胞中。还表明内源性组织蛋白酶抑制剂 B(E 在 31 位),尤其是 EPM1 突变体 R68X 和 Y31-组织蛋白酶抑制剂 B 变体,以及在较小程度上的 EPM1 突变体 G4R,易于在细胞中形成聚集体。